{"denoms":[{"counts":[{"groupId":"BG000","value":"397"},{"groupId":"BG001","value":"393"},{"groupId":"BG002","value":"790"}],"units":"Participants"}],"groups":[{"description":"Patients receive androgen-deprivation therapy (including luteinizing hormone-releasing hormone \\[LHRH\\] agonist therapy, LHRH antagonist therapy, or surgical castration). Patients also receive docetaxel IV over 1 hour on day 1. Treatment with docetaxel repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.","id":"BG000","title":"Androgen-Deprivation Therapy and Docetaxel"},{"description":"Patients receive androgen-deprivation therapy (including luteinizing hormone-releasing hormone \\[LHRH\\] agonist therapy, LHRH antagonist therapy, or surgical castration).","id":"BG001","title":"Androgen-Deprivation Therapy Alone"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"36","upperLimit":"88","value":"64"},{"groupId":"BG001","lowerLimit":"39","upperLimit":"91","value":"63"},{"groupId":"BG002","lowerLimit":"36","upperLimit":"91","value":"63"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"397"},{"groupId":"BG001","value":"393"},{"groupId":"BG002","value":"790"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"}],"populationDescription":"All randomized patients"}